motherlodetv.net
FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”) is pleased to announce that Executive Co-Chairman and CEO Dr. Raza Bokhari, along with the founders, members of the Company’s Board of Directors, members of the leadership team, early investors, advisors, and other stakeholders, will ring the Nasdaq Stock Market opening bell on Wednesday, January 22, 2020, at 9:30 am ET.
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”) announced that its Class B Subordinate Voting Shares (the “Shares”) will commence trading on the Nasdaq Capital Market under the symbol ‘HUGE’ today, January 9, 2020. The Company’s Class B Subordinate Voting Shares will continue to trade on the Canadian Securities Exchange under the symbol ‘HUGE’.
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD Pharma” or the “Company”) today announced that its Class B Subordinate Voting Shares (the “Shares”) have been approved for listing on the NASDAQ Capital Market (“NASDAQ”) under the symbol ‘HUGE’. Trading on the NASDAQ is expected to commence at market open on Thursday, January 9, 2020.
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD Pharma” or the “Company”) today announced the appointments of three key executives: Donal Carroll, Chief Financial Officer. Mr. Carroll previously served as interim CFO; Sandra Lottes, Pharm D, Vice President & Head of Clinical Research of FSD Pharma’s BioSciences Division; and Shahzad Shah, Chief Operating Officer of FV Pharma.
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD Pharma” or the “Company”) announces that Nasdaq has approved its application to have its Class B Subordinate Voting Shares (the “Shares”) listed on the Nasdaq Capital Market (“Nasdaq”). FSD Pharma expects the Shares to commence trading on Nasdaq in the near future.
World-Class Extractions Inc. (CSE:PUMP)(FRA:WCF) (the “Company” or “World-Class“), a vertically integrated provider of advanced extraction and processing systems is pleased to announce the signing of a binding Letter of Intent (“LOI“) to establish a joint venture (the “Joint Venture“) with Canntab Therapeutics Limited (CSE:PILL.CN) (“Canntab“) to set-up, manage and operate a cannabis and hemp extraction and processing facility at Canntab’s manufacturing center in Markham, Ontario (the “Facility“).
World-Class Extractions Inc. (“World-Class” or the “Company“) (CSE: PUMP) (FRA:WCF) is pleased to report the financial and operating results for its first quarter ended July 31, 2019.
World-Class Extractions Inc. (“World-Class”) (CSE:PUMP)(FRA:WCF) announces its first multi-year joint venture agreement (the “Joint Venture“) with FV Pharma Inc. (HUGE) (FSDDF) (0K9), a wholly-owned subsidiary of FSD Pharma Inc. (“FSD“). Under the direction of FV Pharma, World-Class will setup and manage the operations of “Cobra”, a large capacity extraction and processing facility in Cobourg, Ontario, owned by FSD Pharma (the “Facility“) to extract various cannabinoids and other valuable elements from cannabis and hemp plants.
World-Class Extractions Inc. (“World-Class”) (PUMP.CN)(FRA:WCF) announces that it has obtained additional provincial CRN pressure-vessel certification for its proprietary, automated, next-generation “BOSS” CO2 Extraction System. The BOSS is now officially certified in British Columbia, Alberta and Ontario.
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD Pharma” or the “Company”) and Prismic Pharmaceuticals Inc. (“Prismic”), a US-based specialty R&D pharmaceutical company (the “Parties”), announced today that, on June 28, 2019, they finalized the acquisition by FSD Pharma of all of the issued and outstanding securities of Prismic (the “Transaction”). Pursuant to the terms of a previously-announced securities exchange Agreement, FSD Pharma has acquired all outstanding common and preferred shares of Prismic for an aggregate purchase price of approximately US$17.5 million (CAD$23.4 million based on an exchange rate of US$1 to CAD$1.3349), satisfied by the issuance of approximately 102.7 million Class B subordinate voting shares in the capital of FSD Pharma (each, an “FSD Share”) at a deemed price of CAD$0.2275 (US$0.1704) per FSD Share. In addition, FSD Pharma has agreed to assume approximately US$3.05 million of outstanding Prismic long- and short-term liabilities. All of the outstanding Prismic stock options and warrants have been converted into options and warrants to purchase FSD shares, with the number and exercise price of such securities having been adjusted in accordance with the exchange ratio under the Agreement.